17 certified Labor Condition Applications on file with the U.S. Department of Labor, FY2021–FY2024.
Since September 2025, DOL's Project Firewall opens H-1B investigations without waiting for a complaint. These checkpoints come from Syros Pharmaceuticals, Inc.'s own public LCA filings (FY2022–FY2024) — the same records an investigator pulls first.
Withdrawn or denied LCAs are normal in isolation; a high share suggests workers were moved between filings and the paper trail needs checking.
Level I is the entry-level prevailing-wage tier and the band DOL's Project Firewall reviews first for misclassification (senior duties filed at an entry-level wage). The national share is 17%.
Median offered wage is 20% above the DOL prevailing wage across 7 recent certified LCAs. Paying at the floor is lawful, but it invites the question of whether the wage level itself is right.
Each worksite needs its own 10-business-day LCA notice and a PAF record of that posting; a move to a new area of intended employment needs a new LCA before the worker starts there.
No additional recruitment or non-displacement attestations apply.
Public DOL disclosure data can lag actual filings by a quarter. Descriptive only — not legal advice.
Yes — Syros Pharmaceuticals, Inc. sponsors H-1B workers, with 17 certified LCAs on file (FY2021–FY2024), including 1 in FY2024. The median certified salary is $155,000 (P25 $132,919, P75 $167,403). With a 65% transfer share, this employer actively accepts H-1B transfers. 100% of its certified filings meet or exceed the prevailing wage.
Syros Pharmaceuticals, Inc. H-1B sponsorship at a glance, from public U.S. DOL LCA disclosure data (FY2021–FY2024).
Certified LCAs are a prerequisite to H-1B petitions, not visa approvals; one LCA can cover multiple workers. Descriptive only — not legal advice.
The shaded band is the middle half of certified salaries (P25–P75); the bar spans the lowest to highest certified salary.
Levels I–IV are DOL prevailing-wage experience tiers; 89% of filings are senior-level (III–IV).
| Fiscal year | Certified | Denied | Withdrawn | Total |
|---|---|---|---|---|
| FY2021 | 10 | 0 | 0 | 10 |
| FY2022 | 5 | 0 | 0 | 5 |
| FY2023 | 1 | 0 | 0 | 1 |
| FY2024 | 1 | 0 | 3 | 4 |
Case dispositions from the U.S. DOL OFLC disclosure files. Withdrawn are LCAs that were certified and later withdrawn by the employer; they still count toward Total.
| Job title | Salary | Level | Location | Filed | Status |
|---|---|---|---|---|---|
SVP Global Regulatory Affairs & Quality & Op Excellence I-203-24073-796535 | $432,646/yr | IV | Cambridge, MA | Mar 13, 2024 | Certified |
SVP Global Regulatory Affairs & Quality & Op Excellence I-200-24073-796474 | $432,646/yr | IV | Cambridge, MA | Mar 13, 2024 | Withdrawn |
Senior Manager, Financial Planning & Analysis I-200-23251-332086 | $167,403/yr | IV | Cambridge, MA | Sep 08, 2023 | Certified |
SVP Global Regulatory Affairs & Quality & Op Excellence I-203-22227-415818 | $401,362/yr | IV | Cambridge, MA | Aug 15, 2022 | Certified |
Principal Statistical Programmer I-200-22174-307503 | $165,000/yr | IV | Cambridge, MA | Jun 23, 2022 | Certified |
Contracts Manager I-200-22091-031237 | $120,839/yr | II | Cambridge, MA | Apr 01, 2022 | Certified |
Scientist I, Formulation and Drug Product I-200-22053-920154 | $120,000/yr | III | Cambridge, MA | Feb 22, 2022 | Certified |
Senior Scientist, Analytical Development I-200-22026-854070 | $145,000/yr | IV | Cambridge, MA | Jan 26, 2022 | Certified |
Associate Director of Drug Safety I-200-21253-575945 | $200,000/yr | IV | Cambridge, MA | Sep 10, 2021 | Certified |
Research Investigator I-200-21180-432559 | $105,000/yr | II | Cambridge, MA | Jun 29, 2021 | Certified |
Manager, FP&A I-200-21078-159053 | $120,000/yr | III | Cambridge, MA | Mar 18, 2021 | Certified |
Clinical Scientist I-200-21039-061622 | $155,000/yr | IV | Cambridge, MA | Feb 08, 2021 | Certified |
Senior Clinical Trial Manager I-200-21037-060573 | $150,000/yr | IV | Cambridge, MA | Feb 05, 2021 | Certified |
Senior Clinical Scientist I-200-21037-060562 | $155,000/yr | IV | Cambridge, MA | Feb 05, 2021 | Certified |
One row per LCA case (its latest version), from U.S. DOL OFLC disclosure data. Salaries are the offered wage, converted to a yearly figure. Certified LCAs are not visa approvals.
Worker positions by LCA filing purpose, summed across FY2021–FY2024 disclosure records.
Most active filing months: Feb and Mar — useful for timing transfer conversations.
Attestations from the employer's own LCA filings (Form ETA-9035), as disclosed by the U.S. DOL.
1 state · 1 city
The same DOL data on this page is what every H-1B sponsor must track for each worker. ElevateStaffing.ai automates it end-to-end:
Get the private PAF / LCA gap check for your own filings — free, one business day — then let ElevateStaffing.ai keep every LCA, PAF, I-9 and I-983 deadline audit-ready.
Get my private gap check →